ARCT
Arcturus Therapeutics Holdings Inc.
NASDAQ · Healthcare · Biotechnology · US
$15.82
+1.67%Year over year
Reported trailing growth
- Revenue
- -79.1%
- EBITDA
- -45.3%
- EBIT
- -42.1%
- EPS
- -49.3%
- Free cash flow
- -12.1%
- Operating cash flow
- -12.0%
Forward estimates
Based on analyst estimates
- Revenue
- -27.8%
- EBITDA
- -14.4%
- EPS
- -2.7%
Three-year CAGR
- Revenue
- -31.1%
- EBITDA
- +18.9%
- EBIT
- +21.7%
- Net income
- +18.7%
- EPS
- +20.0%
- Free cash flow
- -23.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026